Georgina Long

Georgina Long is a world-leading investigator in melanoma treatment who has conducted landmark trials of combination immunotherapy and targeted therapy strategies. Her research has advanced ipilimumab plus nivolumab in the neoadjuvant setting for high-risk resectable melanoma, demonstrating that neoadjuvant combination checkpoint blockade achieves pathological complete responses in the majority of patients. She has investigated combinations of BRAF/MEK inhibitors with immunotherapy in BRAF-mutated melanoma. Her contributions to adjuvant immunotherapy trials established pembrolizumab, nivolumab, and BRAF/MEK inhibitor combination as standard adjuvant regimens for resected high-risk melanoma. Her clinical research has fundamentally shaped current melanoma treatment paradigms.